Centessa Pharmaceuticals (NASDAQ:CNTA) Sets New 1-Year High

Centessa Pharmaceuticals (NASDAQ:CNTA) reached a new 52-week high, trading as high as $29.42. Analysts have given mixed ratings, with a consensus "Buy" rating and a price target of $34.78. Recent insider sales and institutional investments indicate active trading. The stock's market cap is $3.95 billion, with a P/E ratio of -16.05. Despite missing earnings estimates, analysts forecast -1.6 EPS for the fiscal year.

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) shares reached a new 52-week high on Monday . The company traded as high as $29.42 and last traded at $28.9640, with a volume of 531929 shares traded. The stock had previously closed at $27.98.

Wall Street Analyst Weigh In

Wake Up to This Biotech Stock That Still Has Big Potential Upside

CNTA has been the subject of a number of recent research reports. Oppenheimer started coverage on shares of Centessa Pharmaceuticals in a research report on Friday, August 29th. They issued an "outperform" rating and a $40.00 target price for the company. Chardan Capital upgraded shares of Centessa Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, November 19th. Weiss Ratings reissued a "sell (d-)" rating on shares of Centessa Pharmaceuticals in a report on Wednesday, October 8th. Truist Financial set a $30.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday, November 5th. Finally, Stephens started coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, October 28th. They issued an "overweight" rating and a $35.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $34.78.

Check Out Our Latest Stock Analysis on Centessa Pharmaceuticals

Centessa Pharmaceuticals Trading Up 5.0%

The firm's fifty day simple moving average is $23.83 and its 200 day simple moving average is $18.08. The stock has a market capitalization of $3.95 billion, a P/E ratio of -16.05 and a beta of 1.56. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.02). As a group, equities research analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current fiscal year.

Insider Buying and Selling at Centessa Pharmaceuticals

In related news, CTO Tia L. Bush sold 40,000 shares of the firm's stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $26.00, for a total value of $1,040,000.00. Following the sale, the chief technology officer directly owned 121,503 shares of the company's stock, valued at $3,159,078. This trade represents a 24.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of the business's stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $22.41, for a total value of $134,460.00. Following the transaction, the general counsel directly owned 105,386 shares of the company's stock, valued at approximately $2,361,700.26. The trade was a 5.39% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 179,964 shares of company stock valued at $4,106,481. 7.09% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of hedge funds have recently made changes to their positions in CNTA. China Universal Asset Management Co. Ltd. increased its position in Centessa Pharmaceuticals by 4.8% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 19,181 shares of the company's stock worth $252,000 after purchasing an additional 870 shares in the last quarter. HighMark Wealth Management LLC grew its stake in shares of Centessa Pharmaceuticals by 0.6% during the second quarter. HighMark Wealth Management LLC now owns 237,285 shares of the company's stock worth $3,118,000 after buying an additional 1,500 shares during the last quarter. HighVista Strategies LLC grew its stake in shares of Centessa Pharmaceuticals by 4.3% during the second quarter. HighVista Strategies LLC now owns 40,684 shares of the company's stock worth $535,000 after buying an additional 1,664 shares during the last quarter. Trexquant Investment LP increased its holdings in shares of Centessa Pharmaceuticals by 1.1% during the first quarter. Trexquant Investment LP now owns 263,994 shares of the company's stock worth $3,796,000 after buying an additional 2,810 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its stake in shares of Centessa Pharmaceuticals by 15,209.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock valued at $46,000 after acquiring an additional 3,194 shares during the last quarter. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Company Profile

(Get Free Report)

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

Should You Invest $1,000 in Centessa Pharmaceuticals Right Now?

Before you consider Centessa Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.

While Centessa Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Centessa Pharmaceuticals (NASDAQ:CNTA) Sets New 1-Year High - Time to Buy?